Merck & Co cut global sales force by 12% in 2010
This article was originally published in Scrip
Executive Summary
Merck & Co reduced its global sales force by about 12% in 2010, while its US sales force was cut by almost one third. However, seven of its top 10 products still grew "through the period of maximum disruption", said new CEO Kenneth Frazier, speaking at the annual JP Morgan healthcare conference being held in San Francisco this week. He was referring to the integration of Schering-Plough following its merger with Merck in 2009.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.